If you picked up Barron’s this past weekend, you probably noticed something I’ve been talking about for a while.

Biotech is back.

Barron’s devoted its cover story to what it called a new biotech bull market, and I couldn’t agree more. I’ve been extremely bullish on biotech for the next several years because we’re entering one of the most exciting periods of medical innovation I’ve seen in my career.

And the stocks are finally starting to reflect it. The iShares Biotechnology ETF (IBB) is up about 24% in 2026, while the SPDR S&P Biotech ETF (XBI) has gained roughly 28%. Both are more than doubling the return of the S&P 500 this year.

But one of the most interesting opportunities emerging from this biotech boom has nothing to do with curing cancer or treating some obscure disease.

It’s hair loss.

80 Million Heads, No New Drug Since the ’90s

Pattern hair loss affects an estimated 50 million men and 30 million women in the United States alone. Yet despite the size of that market, there hasn’t been a new prescription treatment approved for pattern hair loss in nearly 30 years.

Think about how unusual that is.

We have AI designing drugs. We can edit genes. We’re developing personalized cancer vaccines. Yet millions of people experiencing hair loss are still largely relying on treatments developed decades ago.

That may finally be changing.

And one of the biggest pharmaceutical companies in the world has apparently noticed.

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, recently said it’s exploring hair loss as part of a broader push into consumer health. The company’s also looking at areas such as menopause and addiction as it searches for opportunities beyond its enormously successful obesity franchise.

If that sounds familiar, it should.

GLP-1 drugs turned obesity from something millions of people simply lived with into one of the largest pharmaceutical markets in the world. Now Wall Street is asking whether hair loss could become another enormous consumer-health category.

I think it’s a fascinating question.

The Hair-Loss Race Is Heating Up

Several smaller companies are already well ahead of Novo.

Cosmo Pharmaceuticals (COPN.SW) is developing Breezula, a topical treatment designed to block androgen receptors directly in the scalp. In two Phase III trials involving 1,465 patients, the treatment produced statistically significant improvements in hair growth. Cosmo has since reported positive longer-term safety data and says it plans to submit the drug for U.S. approval in early 2027.

Jefferies has estimated the drug could eventually generate around $3 billion in global sales.

Then there’s Veradermics (MANE), which is taking a different approach. Its VDPHL01 is an extended-release oral formulation of minoxidil, and the company’s already running late-stage trials.

In one study, men taking the once-daily treatment gained an average 30.3 hairs per square centimeter after six months compared with just 7.3 for placebo. Veradermics has now fully enrolled another confirmatory Phase III study and is also developing the treatment for women.

And then we get to perhaps my favorite part of this story: AI.

Absci (ABSI) is developing ABS-201, an AI-designed antibody targeting the prolactin receptor. Instead of applying something to your scalp every day or taking a daily pill, Absci believes the drug’s long half-life could potentially allow treatment with only a few injections over six months.

It’s still early. ABS-201 is in Phase I/IIa development, so there’s plenty of clinical risk ahead. But Eli Lilly (LLY) recently made a $40 million strategic investment in Absci as part of a $100 million financing, and proof-of-concept data are expected later this year.

This Is Bigger Than Hair

I’m not telling you to run out and buy every hair-loss stock. Biotech remains risky, and plenty of promising drugs never make it through clinical trials.

What interests me is what this says about the larger biotech industry.

We’re watching AI, genomics, massive biological datasets, and increasingly sophisticated drug-discovery platforms converge at the same time. Researchers can search biological possibilities faster, design molecules differently, and attack markets that may have been ignored because the science simply wasn’t good enough.

Hair loss could be one of those markets.

If one of these new treatments delivers dramatically better results than what’s available today, the potential customer base isn’t measured in thousands of patients. It’s measured in tens of millions.

That’s why I’m so bullish on biotech for the next several years. The sector isn’t dependent on one drug, one company, or one breakthrough. Innovation is happening across cancer, obesity, rare diseases, gene editing, AI-designed medicines, and now even hair loss.

20 years ago, hair-loss stocks would’ve sounded like a tiny niche in biotech. Today we’re talking about AI-designed antibodies, novel hormone-blocking drugs, and potentially billions of dollars in annual sales.

The next blockbuster drug doesn’t always have to cure cancer. Sometimes it just has to grow hair.